Literature DB >> 3137243

Evidence of differential control of FSH and LH secretion by gonadotropin-releasing hormone (GnRH) from the use of a GnRH antagonist.

J E Hall1, T D Brodie, T M Badger, J Rivier, W Vale, P M Conn, D Schoenfeld, W F Crowley.   

Abstract

The differential regulation of immunoactive FSH and LH secretion by endogenous GnRH was studied using a GnRH antagonist, [Ac-D2Nal1,D4FPhe2,DTrp3,DArg6]GnRH (the NAL-ARG antagonist), in normal women in the early follicular phase of the menstrual cycle, and their responses were compared to those in two groups of control women. Pulsatile LH secretion was examined as an index of the completeness of blockade of endogenous GnRH secretion. There was a dose-dependent decrease in both the frequency and amplitude of LH pulses. At the highest dose, LH pulses were completely abolished within 20 min after sc administration of the GnRH antagonist and for a minimum of 8 h in all women. The mean plasma LH levels were reduced within the first 4 h after antagonist administration at all doses (P less than 0.001). The duration of LH suppression was influenced by antagonist dose, with a continued effect 24 h after administration of the 500 micrograms/kg dose only. The maximum degree of LH suppression was 40% after 50 micrograms/kg (n = 6), 60% after 150 micrograms/kg (n = 6), and 59% after 500 micrograms/kg (n = 5). In contrast, plasma immunoreactive FSH levels did not change after these doses of the NAL-ARG GnRH antagonist. The maximum degree of FSH suppression was 16%, and the changes in plasma FSH concentrations were not dose dependent. Serum antagonist concentrations rose within 30 min after its administration to mean peak levels of 7.5 +/- 2.1 (+/- SE), 20.4 +/- 6.1, and 151 +/- 21 ng/mL after the 50, 150, and 500 micrograms/kg doses, respectively. The half-time of the disappearance of the NAL-ARG GnRH antagonist from plasma was 8.8 +/- 1.5 h. While there were no effects of antagonist administration on hematological, hepatic, or renal function, three women developed urticaria distant from the site of injection when administered the highest dose. We conclude that blockade of GnRH receptors by a GnRH antagonist 1) effectively antagonizes the action of GnRH, as assessed by its ability to block pulsatile LH secretion and reduce mean plasma LH levels; and 2) inhibits LH release to a considerably greater degree than FSH release, providing further evidence of possible GnRH-independent FSH secretion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137243     DOI: 10.1210/jcem-67-3-524

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Aging attenuates the pituitary response to gonadotropin-releasing hormone.

Authors:  Natalie D Shaw; Serene S Srouji; Stephanie N Histed; Kristin E McCurnin; Janet E Hall
Journal:  J Clin Endocrinol Metab       Date:  2009-06-23       Impact factor: 5.958

2.  Rerouting of a follicle-stimulating hormone analog to the regulated secretory pathway.

Authors:  Christopher A Pearl; Albina Jablonka-Shariff; Irving Boime
Journal:  Endocrinology       Date:  2009-11-03       Impact factor: 4.736

3.  Association Between Fresh Embryo Transfers and Frozen-Thawed Embryo Transfers Regarding Live Birth Rates Among Women Undergoing Long Gonadotropin-Releasing Hormone Antagonist Protocols.

Authors:  Li Fan; Ni Tang; Chunling Yao; Xiaohua Wei; Yongmei Tang; Jingjing Li; Wenjie Huang
Journal:  Front Cell Dev Biol       Date:  2022-04-28

4.  Decreased release of gonadotropin-releasing hormone during the preovulatory midcycle luteinizing hormone surge in normal women.

Authors:  J E Hall; A E Taylor; K A Martin; J Rivier; D A Schoenfeld; W F Crowley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

5.  Sulfation of LH does not affect intracellular trafficking.

Authors:  Christopher A Pearl; Irving Boime
Journal:  Mol Cell Endocrinol       Date:  2009-03-20       Impact factor: 4.102

6.  Cost-effectiveness analysis of GnRH-agonist long-protocol and GnRH-antagonist protocol for in vitro fertilization.

Authors:  Miaomiao Jing; Chenxi Lin; Wenjun Zhu; Xiaoyu Tu; Qi Chen; Xiufang Wang; Youbing Zheng; Runju Zhang
Journal:  Sci Rep       Date:  2020-05-26       Impact factor: 4.379

7.  Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial.

Authors:  Yun Wang; Yanping Kuang; Qiuju Chen; Renfei Cai
Journal:  Trials       Date:  2018-08-22       Impact factor: 2.279

8.  Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men.

Authors:  Richard A Anderson; Jennifer Cormier; Ruth Thieroff-Ekerdt; Malcolm Boyce; Frans van den Berg; Daniel Grau; David Turnquist; Deya Corzo; Philip Graham
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

9.  A novel carboxyl-terminal heptapeptide initiates the regulated secretion of LH from unique sub-domains of the ER.

Authors:  Albina Jablonka-Shariff; Irving Boime
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

10.  Comparison of the Cumulative Live Birth Rates of Progestin-Primed Ovarian Stimulation and Flexible GnRH Antagonist Protocols in Patients With Low Prognosis.

Authors:  Mingze Du; Junwei Zhang; Zhen Li; Xinmi Liu; Jing Li; Wenxia Liu; Yichun Guan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-13       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.